Here are three things to know.
1. Attorney General Jeff Sessions announced the proposed change during a speech in North Carolina.
“Under this proposed new rule, if DEA believes that a company’s opioids are being diverted for misuse, then they will reduce the amount of opioids that company can make,” he said, according to The Hill.
2. The rule would also require the DEA to solicit input from stakeholders in other federal agencies, like the CDC and FDA, when setting manufacturing quotas.
3. The regulatory action follows a lawsuit West Virginia filed against the DEA in December, claiming the agency’s drug quota rule “wrongfully sets manufacturing quotas based on the amounts of pills that drugmakers expect to sell, not on legitimate medical needs,” according to Reuters. West Virginia leaders argued this approach has contributed to the illegal diversion of pain medication amid a worsening opioid epidemic.
More articles on opioids:
Feds call for more medication-based opioid treatment: 7 takeaways
Daily presurgery opioid use linked to poorer spine surgery outcomes
AMA opposes opioid prescription limits: 5 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.